Stay ahead of trial enrollment trends, FDA decisions, and site activation updates. Trusted by CROs, site coordinators, and clinical research professionals.
Free forever. Unsubscribe anytime. No spam.
Want deeper analysis? Check out our premium tier.
Everything clinical research professionals need to stay informed, delivered daily.
Daily updates on enrollment trends, patient recruitment strategies, site performance metrics, and competitive trial landscape analysis.
New guidance documents, approval decisions, protocol amendments, safety alerts, and regulatory policy changes affecting clinical trials.
Site start-up timelines, coordinator training opportunities, trial logistics, supply chain updates, and operational best practices.
Decentralized trial models, adaptive designs, technology platforms, digital endpoints, and innovative approaches transforming clinical research.
From site coordinators to CRO executives, BioMed Nexus serves the entire clinical research ecosystem.
Trial-specific intelligence that generic industry newsletters miss.
Everything you need to know about our clinical trial newsletter.
Join 22,000+ clinical research professionals who trust BioMed Nexus for their daily trial intelligence.
Free forever. Unsubscribe anytime. No spam.
Want deeper analysis? Check out our premium tier.
Breakthroughs, pipelines, data drops, and deals shaping the biotech landscape.
The science works. The manufacturing doesn’t scale. That is the central tension in cell and gene therapy right now. More than 3,000 cell and gene therapy clinical trials are active worldwide. Over two dozen CGT products have received regulatory approval. And nearly $15 billion flowed
More than 200 AI-designed drugs are now in clinical development. Phase I success rates for AI-discovered compounds are running between 80% and 90%, roughly double the historical average. The first fully AI-designed drug has posted positive Phase IIa efficacy data in humans. And in the
Every breakthrough drug has an invisible army behind it. Not just the scientists in lab coats or the executives signing deals — but the platforms, tools, and service companies that form the infrastructure of modern drug development. From the AI systems designing molecules to the
What Is a Biomarker: Modern medicine runs on measurement. Before treating a disease, you need to detect it. Before knowing if a drug works, you need to track its effects. Before predicting who will respond to therapy, you need signals that distinguish responders from non-responders.
Device innovation, diagnostics, tools, and platforms redefining patient care.
Not every drug works for every patient. In oncology, response rates to targeted therapies often range from 20% to 40% in unselected populations. The majority of patients receive treatments that won’t help them — exposing them to side effects without benefit. Companion diagnostics change this
Durham-based VC firm closes largest funding round amid sector downturn, marking 25 years and 100th portfolio investment Hatteras Venture Partners has closed two investment funds with a total of $200 million in commitments, announced Wednesday morning, representing the firm’s largest fundraising to date and a
Strategic deal adds premium implantable lens technology at 51% premium to strengthen refractive surgery position Alcon announced its agreement to acquire STAAR Surgical for approximately $1.5 billion in an all-cash transaction valued at $28 per share, representing a 51% premium that sent STAAR shares soaring
The FDA has granted clearance to Nyxoah’s innovative Genio system, a breakthrough hypoglossal nerve stimulation device designed to treat obstructive sleep apnea. This regulatory approval marks a significant milestone in sleep medicine, offering patients a new minimally invasive treatment option that could transform care for
Regulatory moves, commercial strategy, and major therapeutic developments.
The first new mechanism for schizophrenia in 70 years launched in late 2024. Now, as we enter Q1 2026, we have enough data to assess what Cobenfy means for patients, prescribers, and investors. The verdict: a quiet revolution is underway—one that will take years to
The era of 15% weight loss is over. We are now entering the 30% era. Eli Lilly’s retatrutide has delivered 28.7% weight loss in its first Phase 3 trial, while Novo Nordisk’s CagriSema achieved 22.7% in REDEFINE 1—both representing a generational leap beyond current GLP-1
Executive Takeaway The FDA approved 46 novel drugs in 2025, four fewer than 2024’s 50 approvals but still above the historic average of 36 new drugs per year since 1993. The five-year rolling average now sits at 48 approvals annually. Small molecules dominated at 65%
The shift from intravenous to subcutaneous drug administration is accelerating across oncology and immunology, fundamentally changing how patients receive treatment and how healthcare systems manage capacity. With Keytruda QLEX recently approved in the U.S. and new durability data for subcutaneous Ocrevus, we’re witnessing a transformation
BioMed Nexus delivers a fast, daily industry briefing for leaders across biotech, medtech, and pharma. Every weekday morning, we curate the most important developments, high-signal insights, and need-to-know updates so you can stay informed, move quickly, and make confident decisions in a rapidly evolving landscape.
